174 related articles for article (PubMed ID: 26457537)
41. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.
Kostrhunova H; Vrana O; Suchankova T; Gibson D; Kasparkova J; Brabec V
Chem Res Toxicol; 2010 Nov; 23(11):1833-42. PubMed ID: 20939593
[TBL] [Abstract][Full Text] [Related]
42. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
43. Molecular aspects of antitumor effects of a new platinum(IV) drug.
Kaspárková J; Nováková O; Vrána O; Intini F; Natile G; Brabec V
Mol Pharmacol; 2006 Nov; 70(5):1708-19. PubMed ID: 16896071
[TBL] [Abstract][Full Text] [Related]
44. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
45. Cytotoxic acridinylthiourea and its platinum conjugate produce enzyme-mediated DNA strand breaks.
Brow JM; Pleatman CR; Bierbach U
Bioorg Med Chem Lett; 2002 Oct; 12(20):2953-5. PubMed ID: 12270182
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of DNA Synthesis by a Platinum-Acridine Hybrid Agent Leads to Potent Cell Kill in Non-Small Cell Lung Cancer.
Smyre CL; Saluta G; Kute TE; Kucera GL; Bierbach U
ACS Med Chem Lett; 2011 Aug; 2(11):870-874. PubMed ID: 22328962
[TBL] [Abstract][Full Text] [Related]
47. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
Malina J; Natile G; Brabec V
Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
[TBL] [Abstract][Full Text] [Related]
48. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
[TBL] [Abstract][Full Text] [Related]
49. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks.
Saleh-Gohari N; Bryant HE; Schultz N; Parker KM; Cassel TN; Helleday T
Mol Cell Biol; 2005 Aug; 25(16):7158-69. PubMed ID: 16055725
[TBL] [Abstract][Full Text] [Related]
50. Relationships between cisplatin-induced adducts and DNA strand-breaks, mutation and recombination in vivo in somatic cells of Drosophila melanogaster, under different conditions of nucleotide excision repair.
García Sar D; Aguado L; Montes Bayón M; Comendador MA; Blanco González E; Sanz-Medel A; Sierra LM
Mutat Res; 2012 Jan; 741(1-2):81-8. PubMed ID: 22108251
[TBL] [Abstract][Full Text] [Related]
51. Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents.
Cincinelli R; Musso L; Dallavalle S; Artali R; Tinelli S; Colangelo D; Zunino F; De Cesare M; Beretta GL; Zaffaroni N
Eur J Med Chem; 2013 May; 63():387-400. PubMed ID: 23517728
[TBL] [Abstract][Full Text] [Related]
52. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
53. The distinctive cellular responses to DNA strand breaks caused by a DNA topoisomerase I poison in conjunction with DNA replication and RNA transcription.
Sakasai R; Iwabuchi K
Genes Genet Syst; 2016; 90(4):187-94. PubMed ID: 26616758
[TBL] [Abstract][Full Text] [Related]
54. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
55. Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand.
Kasparkova J; Suchankova T; Halamikova A; Zerzankova L; Vrana O; Margiotta N; Natile G; Brabec V
Biochem Pharmacol; 2010 Feb; 79(4):552-64. PubMed ID: 19782655
[TBL] [Abstract][Full Text] [Related]
56. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
57. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.
Dzagnidze A; Katsarava Z; Makhalova J; Liedert B; Yoon MS; Kaube H; Limmroth V; Thomale J
J Neurosci; 2007 Aug; 27(35):9451-7. PubMed ID: 17728458
[TBL] [Abstract][Full Text] [Related]
58. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
Ahmad S
Chem Biodivers; 2010 Mar; 7(3):543-66. PubMed ID: 20232326
[TBL] [Abstract][Full Text] [Related]
59. Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates.
Baruah H; Rector CL; Monnier SM; Bierbach U
Biochem Pharmacol; 2002 Jul; 64(2):191-200. PubMed ID: 12123739
[TBL] [Abstract][Full Text] [Related]
60. Molecular aspects of resistance to antitumor platinum drugs.
Brabec V; Kasparkova J
Drug Resist Updat; 2002; 5(3-4):147-61. PubMed ID: 12237082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
